stockrowNanobiotix S.A. - Sponsored ADR
NBTX Healthcare Biotechnology
Nanobiotix S.A. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $36.9 million.
Follow NBTX
Alert me
Nanobiotix S.A. - Sponsored ADR (NBTX) EV/Sales
As of 6 November 2026, Nanobiotix S.A. - Sponsored ADR (NBTX) trades at a EV/Sales of 5,356×. Over the past ten years it has ranged from 234× (June 2022) to 10,908× (May 2026); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4,526× | 742.05% |
| FY2024 | 537× | (53.95%) |
| FY2023 | 1,167× | 45.34% |
| FY2022 | 803× | (29.94%) |
| FY2021 | 1,146× | (40.21%) |
| FY2020 | 1,918× | (14.37%) |
| FY2019 | 2,239× | 0.00% |
| FY2018 | 2,239× | 0.00% |
| FY2017 | 2,239× | 0.00% |
| FY2016 | 2,239× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2021 | 5,576× | 37.49% |
| Dec 2020 | 4,056× | 64.38% |
| Jun 2020 | 2,467× | 0.00% |
| Dec 2019 | 2,467× | 10.17% |
| 2 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BRVE Braveheart Bio, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | 1.8× |
| NUVB Nuvation Bio Inc. compare | 5.4× |
| PGEN Precigen, Inc. compare | 10.5× |
| NTLA Intellia Therapeutics, Inc. compare | 20.9× |
| SLS SELLAS Life Sciences Group, Inc. compare | 136× |
| NBTX Nanobiotix S.A. - Sponsored ADR | 5,356× |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)